Kcs Wealth Advisory Athenex, Inc. Transaction History

Kcs Wealth Advisory

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 26, 2022	SELL	$1.36 - $2.94 $14,391 - $31,111	-10,582 Closed	0 $0
Q3 2021 Oct 20, 2021	BUY	$2.97 - $4.84 $1,485 - $2,420	500 Added 4.96%	10,582 $32,000
Q2 2021 Jul 27, 2021	SELL	$3.71 - $5.13 $38,955 - $53,865	-10,500 Reduced 51.02%	10,082 $47,000
Q2 2019 Jul 29, 2019	BUY	$9.44 - $19.8 $79,296 - $166,320	8,400 Added 68.95%	20,582 $408,000
Q4 2018 Jan 17, 2019	BUY	$10.24 - $15.49 $10,240 - $15,490	1,000 Added 8.94%	12,182 $155,000
Q3 2018 Nov 06, 2018	BUY	$15.53 - $19.97 $10,591 - $13,619	682 Added 6.5%	11,182 $174,000
Q1 2018 May 04, 2018	BUY	$13.53 - $17.47 $142,065 - $183,435	10,500 New	10,500 $179,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Kcs Wealth Advisory, based on Form 13F filings with the SEC.

Stay updated on Kcs Wealth Advisory with notifications on news.